New graphic cigarette warning labels released last month by the Food and Drug Administration already appear to be having one desired effect: an increase in "quit smoking" queries to the national 1-800-QUIT-NOW smoking cessation line, the Associated Press reported Saturday.
The latest vindicator to the almost $3.5 billion vitamin and supplement business across all outlets isn’t positive press. It’s not even the continued consumer gravitation toward self-care. It’s Wall Street.
Adding an investigational drug for Type 2 diabetes to the common generic drug metformin helped control blood sugar in patients who could not control their blood sugar with metformin alone, according to results of a late-stage clinical study.
Important safety information often is missing from drug labels, while some pharmacies don’t include medication guides required by the federal government, according to a new investigation by Consumer Reports.
In an effort to help those suffering from acne, La Roche-Posay has introduced its new Effaclar K Daily Renovating Anti-Relapse Acne Treatment 1, a daily treatment to address the ongoing, recurring life cycle of acne.
An investigational Sanofi drug for diabetes works at least as well as a similar treatment already on the market, and results in less abnormally low blood sugar, according to late-stage clinical trial results presented at the American Diabetes Association’s 71st Scientific Sessions in San Diego this past weekend.
The Obama administration recently called on the public for ideas to streamline federal regulations. In response, the National Association of Chain Drug Stores has sent its suggestion to the Food and Drug Administration.
A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.